Susumu Miyamoto

Kyoto University

Disclosure: Nothing to disclose

Presentation(s):

• PDTM-15 - Embryonic stem cell signature drives atypical teratoid/rhabdoid tumor development in human pluripotent stem cell-derived tumor model

  Friday, November 22
  8:14 PM – 8:18 PM

• ACTR-01 - Phase I/II Study of Temozolomide Plus NimustineChemotherapy for Recurrent Malignant Gliomas:Kyoto Neuro-oncology Group

  Saturday, November 23
  5:00 PM – 7:00 PM